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Abstract: Trytophan Hydroxylase Type I (TPH1), most abundantly expressed in the gastrointestinal tract, initiates the 
synthesis of serotonin by catalyzing hydroxylation of tryptophan in the presence of biopterin and oxygen. We have previ-
ously described three series of novel, periphery-specific TPH1 inhibitors that selectively deplete serotonin in the gastroin-
testinal tract. We have now determined co-crystal structures of TPH1 with three of these inhibitors at high resolution. 
Analysis of the structural data showed that each of the three inhibitors fills the tryptophan binding pocket of TPH1 with-
out reaching into the binding site of the cofactor pterin, and induces major conformational changes of the enzyme. The 
enzyme-inhibitor complexes assume a compact conformation that is similar to the one in tryptophan complex. Kinetic 
analysis showed that all three inhibitors are competitive versus the substrate tryptophan, consistent with the structural data 
that the compounds occupy the tryptophan binding site. On the other hand, all three inhibitors appear to be uncompetitive 
versus the cofactor 6-methyltetrahydropterin, which is not only consistent with the structural data but also indicate that the 
hydroxylation reaction follows an ordered binding mechanism in which a productive complex is formed only if trypto-
phan binds only after pterin, similar to the kinetic mechanisms of tyrosine and phenylalanine hydroxylase. 
Keywords: Serotonin, structure, kinetics, gastrointestinal disorder, carcinoid, monooxygenase. 
INTRODUCTION 
  Serotonin (5-hydroxytryptamine, 5-HT) has a plethora of 
functions in both the central nervous system and the periph-
ery. It is synthesized from tryptophan by the sequential ac-
tion of two enzymes, tryptophan hydroxylase (TPH) and 
aromatic amino acid decarboxylase with TPH catalyzing the 
rate-limiting step. Two forms of TPH have been identified in 
mammals: TPH1, expressed highly in the gastrointestinal 
tract and the pineal gland, is responsible for >90% of 5-HT 
synthesis in the periphery, while TPH2, expressed in neu-
ronal cells located in the dorsal raphe nucleus of the brain 
and the myenteric plexus of the gut, is responsible for the 
vast majority of 5-HT synthesis in the central nervous sys-
tem [1-4]. The two enzymes, sharing an overall identity of 
~80% at the amino acid level, are homologous to the other 
two aromatic amino acid hydroxylases, phenylalanine hy-
droxylase (PAH) and tyrosine hydroxylase (TH), with ap-
proximately 50% amino acid sequence identity [3, 5]. The 
four enzymes use the same cofactors, tetrahydrobiopterin, 
iron, and oxygen to catalyze the hydroxylation of their re-
spective substrates [6].  
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  X-ray crystal structures have been determined for various 
forms of TPH1, PAH and TH [7-13]. The catalytic domains 
of all three enzymes have a very similar fold with a mixture f 
 and  structures. The active site is formed by two long 
channels, one occupied by the amino acid substrate, the other 
one by pterin, with iron sitting at the intersection of the two 
channels. For PAH, binding of 5,6,7,8-tetrahydro-L-
biopterin (BH4) caused small structural changes to the cata-
lytic domain [8]. In contrast, binding of a phenylalanine ana-
logue, such as L-norleucine or 3-(2-thienyl)-L-alanine 
(THA) in the presence of BH4 and iron ion led to large struc-
tural changes in the catalytic domain [9, 14]. Specifically, 
the loop containing residues 133-141 of PAH moved much 
closer to the catalytic site. For TPH1, a structure of the cata-
lytic domain of the human enzyme with 7,8-dihydrobiopterin 
(BH2) and ferric iron ion bound was solved first, which 
showed remarkable similarity to the structure of the catalytic 
domain of PAH with BH4 bound [11]. More recently, a 
structure of the catalytic domain of chicken TPH1 with tryp-
tophan bound was solved [12]. Compared with the BH2-
bound structure of human TPH1, binding of tryptophan 
caused major structural changes with two loops (Leu124-
Asp139 and Ile367-Thr369) brought closer to the catalytic 
site, as in the corresponding regions of PAH after substrate 
analogue binding [12].  
  The kinetic mechanism of mammalian TH and bacterial 
PAH has been determined. For both enzymes, all three sub-
strates, i.e., amino acid, pterin, and oxygen, have to be bound 
before catalysis can happen [6]. For rat TH, the order of sub-
strate binding is pterin first, followed by oxygen, and then 20    Current Chemical Genomics, 2010, Volume 4  Cianchetta et al. 
tyrosine [15]. For bacterial PAH, one study reported oxygen 
binding first, followed by pterin and amino acid in random 
order [16]. A more recent study, however, conclusively 
showed that pterin binds first, followed by phenylalanine and 
then oxygen [17]. Such an ordered binding mechanism with 
pterin binding first is consistent with the observations that 
both enzymes are inhibited by their amino acid substrates at 
high concentrations [6]. TPH1 is also inhibited by high con-
centrations of Trp [18], implicating a similar kinetic mecha-
nism , even though no detailed mechanism studies have been 
reported. 
  Dysregulation of the serotonergic system in the periphery 
is associated with various kinds of maladies, including che-
motherapy-induced nausea and vomiting [19], gastrointesti-
nal disorders [20, 21], and pulmonary hypertension [22]. 
Inhibition of TPH1 will lead to decrease or total abolishment 
of serotonin synthesis, and thus may provide effective treat-
ment for such disorders that are caused by excessive synthe-
sis or release of serotonin. Previously, we reported the dis-
covery and characterization as well as structure-activity rela-
tionship of three series of novel TPH1 inhibitors that are able 
to deplete peripheral but not central serotonin [4, 23, 24]. We 
have now determined X-ray structures of the catalytic do-
main of human TPH1 co-crystallized with one compound 
from each of the three series of inhibitors. Hereby, we report 
the structure and analysis of the co-crystals. We also carried 
out kinetic studies of the three inhibitors in attempt to under-
stand their mechanism of inhibition. 
MATERIALS AND METHODS 
Materials 
  Compounds LP-521834, LP-533401, and LP-534193 
were synthesized in-house as described before [23, 24]. All 
other reagents were purchased from Sigma-Aldrich.  
Protein Purification, Crystallization, and Data Collection 
  The polypeptide encompassing amino acid sequence 102 
to 402 of human TPH1 with a C-terminal six-histidine tag 
was produced in E. coli BL21(DE3) cells using a modified 
pET28 expression vector. The protein was purified by Ni
2+ 
affinity, anion exchange, and gel filtration chromatography 
essentially as described previously [11]. The final protein 
buffer contained 50 mM Tris-Cl, pH 8.0, 0.5 mM EDTA, 1 
mM DTT and 200 mM NaCl. For co-crystallization, inhibi-
tor (from a 100 mM DMSO stock) was added to the purified 
enzyme to a final concentration of 0.5 mM and the resulting 
complex was concentrated to a final protein concentration of 
10-15 mg/ml with a Centricon centrifugal concentrator. To 
obtain crystals, hanging drop vapor diffusion was employed 
(20º C), using drops containing a 1:1 ratio of the concen-
trated protein solution and a reservoir comprising 24-28% 
(w/v) PEG 6000, and 100 mM Tris-Cl, pH 8.5. Crystals were 
cryoprotected by brief immersion in the reservoir solution 
supplemented with 20% (v/v) ethylene glycol, harvested in 
nylon loops and frozen in liquid nitrogen for data collection. 
X-ray data were collected at beamline 4.2.2 at the ALS, Ber-
keley, at 10000 eV on a Noir1 CCD detector. Data were ana-
lyzed and reduced using d*TREK [25] and CCP4 [26]. The 
complex structures were solved by molecular replacement 
using the structure of human TPH1 bound with BH2 and 
Fe(III) [11] as a probe. The molecular replacement calcula-
tions were carried using PHASER in the CCP4 suite2. The 
structures were refined using REFMAC in the CCP4 suite2. 
All electron density map visualization and manual model 
rebuilding was carried out using the XtalView/Xfit package 
[27].  
Enzyme Kinetic Studies 
  Full-length human TPH1 was expressed and purified as 
described before [4], to a specific activity of approximately 
60 nmole/min/(mg of protein). Enzyme assays were carried 
out at room temperature with atmosphere oxygen in a vol-
ume of 0.1 ml containing 50 mM 3-(N-morpholino)-
propanesulfonate (MOPS), pH 7.2, 100 mM (NH4)2SO4, 0.05 
mg/ml of catalase, 1 mg/ml of bovine serum albumin, 0.05 
mM (NH4)2Fe(SO4)2 , various concentrations of tryptophan 
and 6-methyltetrahydropterin, and 0.5 μg of TPH1. The reac-
tions were started with the addition of pterin and were gener-
ally linear with time up to 10 min. For kinetic studies, the 
reactions proceeded for 5 min with 0.5 μg of protein per re-
action in the presence of the inhibitors at the indicated con-
centrations and were then terminated immediately with 0.1 
ml of 1 M trichloroacetic acid. The reaction mixtures were 
filtered through GF/B filter plates; five ul of each filtrate was 
then analyzed for 5-HTP using in-line fluorescence-coupled 
HPLC as described before [4]. Double reciprocal plots were 
used to determine type of inhibition. Competitive Ki’s of the 
inhibitors were calculated using the global fit formula 
(GraphPad Prism 4.03): v = Vmax*[S]/(KmObs + [S]), 
where v = initial velocity, Vmax = maximum velocity, [S] = 
substrate concentration, [I] = inhibitor concentration, KmObs 
= Km*(1+[I]/Ki), and Km = Michaelis-Menten constant 
[28]. Uncompetitive Ki’s of the inhibitors were calculated 
using the global fit formula v = [S]*Vmax*KmObs/Km/ 
(KmObs+[S]), where v, [S], Km, Vmax, and [I] are as de-
fined above except that KmObs = Km/(1+[I]/Ki) [28].  
RESULTS 
Crystal Structures of Inhibitor-TPH1 Complexes 
  To gain a better understanding of the interactions be-
tween TPH1 and its inhibitors, we solved co-crystal struc-
tures of the catalytic domain of human TPH1 with three of 
our TPH1 inhibitors, LP-521834, LP-533401, and LP-
534193 at a resolution of 1.80, 1.85, and 1.92 Å, respec-
tively. All three crystal structures were determined with one 
iron ion plus one inhibitor molecule but without pterin. The 
coordinates are deposited in Protein Data Bank and desig-
nated as 3HF6 (TPH1 +LP-521834), 3HF8 (TPH1 + LP-
533401), and 3HFB (TPH1 + LP-534193). Due to poor elec-
tron density, loops 122-137 in 3HF8 and 3HFB, and 119-128 
in 3HF6 were not resolved. The three inhibitor molecules 
share a phenylalanine moiety but represent three distinct 
subtypes on the basis of substitutions on the phenylalanine 
moiety (Fig. 1). They all contain four ring structures which, 
for the purpose of clarity, are designated A to D (Fig. 1).  
  Analysis of the three X-ray structures shows that TPH1 
has a catalytic core composed of mixed  and  structures, 
similar to that of human PAH and rat TH, as noted previ-
ously [11]. The active site is formed by a large cavity di-
vided into a ~13 Å long channel, where the amino acid part 
of the inhibitors is bound, and a ~9 Å long chamber previ-
ously identified as the BH2 binding site [11]. Approximately Structure and Mechanism of Tryptophan Hydroxylase Type I  Current Chemical Genomics, 2010, Volume 4    21 
at the conjunction of the two areas, the active site is exposed 
to the solvent through a roughly circular, ~12Å wide open-
ing. The iron ion is situated at the intersection of the two 
areas and coordinated to His272, His277, three water mole-
cules, and to Glu317 with a monodentate interaction in 3HF6 
(LP-521834) and 3HFB (LP-534193). This pattern of iron 
coordination is identical to that observed in human PAH-
BH4-Fe(II) and TPH1-BH2-Fe(III) complexes [8, 11]. In 
contrast, the iron ion in 3HF8 (LP-533401) is coordinated to 
His272, His277, one water molecule and to Glu317 with a 
bidentate interaction. Such a bidentate arrangement of the 
metal ligand was only observed in TPH1-Trp-Fe(III) and 
PAH-BH4-THA-Fe(II) complexes [9, 12]. The oxidation 
state of the iron in the three structures was not resolved, but 
it can be assumed to be ferric since the enzyme purification 
and crystallization were carried out under aerobic conditions. 
  The Tyr235 residue showed different orientations in the 
three structures: in 3HF8 and 3HFB, its side chain is directed 
inward and forms a hydrogen-bond with the backbone car-
bonyl of Pro268 which, through a bridging water molecule, 
interacts with Thr367 backbone nitrogen. In this conforma-
tion, the Tyr side chain is almost orthogonal to the equiva-
lent Tyr236 in the chicken TPH1 X-ray structure 3E2T [12]. 
In 3HF6, the Tyr235 side chain is rotated outward approxi-
mately 90 
o, bringing the aromatic ring to an almost coplanar 
position with that of Ty236 in the chicken TPH1 X-ray struc-
ture accompanied by a ~5 Å shift toward the solvent. An 
additional change observed in all three structures is that the 
loop Ile336-Phe369 moved toward the loop Phe263-Pro266 
when compared to the TPH1-BH2-Fe(III) structure, as in the 
corresponding loop of chicken TPH1 in the Trp complex 
[12]. 
Analysis of the Binding Modes of the Ligands 
  Analysis of the ligands’ binding mode reveals that the 
three compounds form similar interactions with TPH1. The 
2-amino-3-phenyl-propionic acid (phenylalanine) part is a 
common substructure across the ligands and, not surpris-
ingly, the interactions between this moiety and the protein 
are almost the same in the three structures, as shown in Fig. 
(2). The carboxylate group interacts with Arg257 through a 
salt-bridge and accepts two hydrogen bonds: one from the 
backbone nitrogen of Thr265 and another one from the hy-
droxyl group of the side chain of Ser336. Similar interactions 
occur between the carboxylate group of tryptophan and 
Arg258, Thr266, and Ser337 in the chicken TPH1-Trp-
Fe(III) structure, and between the carboxylate group of THA 
and Arg270, Thr278, Ser349 in PAH-BH4-THA-Fe(II) 
structure. The primary amine group, protonated at physio-
logical pH, forms a hydrogen-bond with the carbonyl oxygen 
of Thr265, and two interactions with water molecules in 
3HF6 and 3HF8 but only one in 3HFB, also similar to the 
interaction between the primary amine of Trp with the car-
bonyl oxygen of Thr266 and two water molecules in the 
chicken TPH1-Trp-Fe(III) structure. In addition, similar to 
the structure of the chicken TPH1 (3E2T), the aromatic sur-
face of Tyr264 closes this section of the binding pocket (Fig. 
2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Interactions between TPH1 and the amino acid portion of 
the ligands. 
 
  Ring A of the inhibitors is ~3.75 Å from the almost co-
planar side chain of Pro268 and interacts with the iron ion-
coordinating His272 (Fig. 2). Distinct from what was ob-
served in the X-ray structure of PAH co-crystallized with 
THA where the thiophene ring interacted with His285 
through a face-to-face-- interaction, no stacking interac-
tion was observed between Ring A and His272. In the struc-
tures presented here, in fact, Ring A is rotated ~70° away 
from the plane of the imidazole and makes hydrophobic con-
tacts with the side chain of Pro268 (Fig. 2). Overall, the data 
indicate that the phenylalanine moiety in all three com-
pounds binds to the enzyme in a way that is highly similar to 
the way in which the substrate tryptophan binds in the 
chicken TPH1-Trp-Fe(III) complex.  
  The three ligands have different moieties as Ring B: 2-
amino-triazine in LP-521834, 2-amino-pyrimidine in LP-
533401, and pyrazine in LP-534193. Two interactions be-
tween Ring B and the enzyme are shared among the three 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Structure and ring designation of the three inhibitors: from 
top to bottome, LP-521834, LP-533401, and LP-534193. 
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structures: the edge-to-face - interaction with Phe313 and 
the contact between the nitrogen atoms in the ortho position 
relative to phenylalanine and one of the iron ion-
coordinating water molecules. The two ligands with a 2-
amino group, i.e., LP-521834 and LP-533401, show two 
additional hydrogen bonds: one with the side chain of 
Glu317 and the other with a water molecule (Fig. 3). In addi-
tion, LP-521834 accepts a hydrogen bond from water 449 
(Fig. 3).  
  The remaining parts of the ligands (linker and Rings C 
and D) establish less specific interactions with TPH1: no 
hydrogen bond was observed between the protein and these 
substructures; only hydrophobic and - interactions are 
found. This part of the ligands is the least analogous, and 
thus showed different conformations and interactions with 
TPH1 in the three complexes (Fig.  4). In 3HF6, LP-521834, 
most distinct from the other two in the ring C/D moiety, ex-
ploits a peculiar conformation of Tyr235 by having its 
naphthyl structure sandwiched between the Tyr235 side 
chain (--face-to-face stacking) and Pro268 (hydrophobic 
interaction). In 3HF8, the CF3 group of LP-533401 is placed 
in a small hydrophobic pocket located at the entrance to the 
catalytic site defined by Ile336, Leu365, Cys364 and 
Phe313. Ring C makes hydrophobic contact with Pro238 and 
Tyr235 while Ring D is placed on the protein's external sur-
face at the entrance to the binding pocket in an area defined 
by the Pro238 side chain and backbone atoms of Ser237 and 
Leu236. In 3HFB, LP-534193 has Ring D interacting with 
Pro238 and Ring C in a hydrophobic pocket defined by 
Ala309, Cys364 and Phe313.  
  The human TPH1-BH2-Fe(III) structure [11] shows that 
Tyr235 and Pro238 interact with pterin. Superposition of this 
X-ray structure on 3HF6, 3HFB and 3HF8 reveals that the 
three inhibitors do not occupy the pterin binding pocket (Fig. 
5). Whether a pterin molecule and any of the inhibitors can 
bind to the enzyme simultaneously remains to be tested ex-
perimentally. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Superposition of 3HF6, 3HF8, 3HFB and 1MLW shows 
that the three inhibitors do not occupy the pterin binding pocket. 
 
Kinetic Analysis of Inhibition 
  We also studied mechanism of inhibition of the three 
inhibitors with purified recombinant full-length TPH1. When 
tryptophan concentration was varied at a fixed concentration 
of the pterin cofactor 6-methyltetrahydropterin (6-MePH4), 
all three inhibitors displayed characteristics of competitive 
inhibition, as shown by the lines converging on the Y axis in 
the double reciprocal plots of the data (Figs. 6A, 6C, and 
 
 
 
 
 
 
 
 
 
Fig. (3). Interactions between TPH1 and Ring B of the inhibitors. The contact with one of the iron-coordinating water and the edge-to-face -
 interaction with Phe313 are common to the three complexes. LP-521834, left panel; LP-533401, middle panel; LP-534193, right panel. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Different conformations of Ring C and D in the three 
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6E). The Ki values of LP-533401, LP-521834, and LP-
534193, determined using non-linear regression based on 
competitive inhibition, are 0.31, 0.036, and 0.03 μM, respec-
tively (Table 1). The finding that all three compounds are 
competitive versus tryptophan is entirely consistent with the 
observations from the X-ray structures that all three inhibi-
tors occupy the binding site of tryptophan. On the other 
hand, when 6-MePH4 concentration was varied at a fixed 
concentration of tryptophan, all three compounds appeared 
to be uncompetitive, as shown by the lines being nearly par-
allel in the double reciprocal plots (Figs. 6B, 6D, 6F). The 
Ki values for LP-533401, LP-521834, and LP-534193, de-
termined using non-linear regression fitting based on un-
competitive inhibition, are 0.81, 0.19, and 0.17 μM, respec-
tively. The finding that all three inhibitors are not competi-
tive versus pterin is consistent with the structural data that 
they don’t occupy the pterin binding site. Since uncompeti-
tive behavior is typically displayed by inhibitors that can 
bind to the enzyme only after the varied substrate is bound 
[28], the data suggest that the inhibitors can only bind to the 
enzyme after pterin is bound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Double reciprocal plots of initial velocities at various concentration of the inhibitors: LP-533401 (A, B), LP-521834 (C, D), and LP-
534193 (E, F). A, C, E, varying tryptophan concentration at a fixed concentration of 6-MePH4 (200 uM). B, D, F, varying 6-MePH4 at fixed 
concentration of tryptophan (50 uM). The inhibitor concentrations used here are: A, LP-533401 at 0 uM (), 0.25 uM (), 0.5 uM (), and 
1.0 uM (); B, LP-533401 at 0 uM (), 0.5 uM (), 1.0 uM (), and 2.0 uM (); C, LP-521834 at 0 uM (), 0.05 uM (), 0.15 uM (), 
and 0.5 uM (); D, LP-521834 at 0 uM (), 0.2 uM (), 0.5 uM (), and 1.0 uM (); E, LP-534193 at 0 uM (), 0.05 uM (), 0.15 uM 
(), and 0.5 uM (); F, LP-534193 at 0 uM (), 0.2 uM (), 0.5 uM (), and 1.0 uM (). 24    Current Chemical Genomics, 2010, Volume 4  Cianchetta et al. 
DISCUSSION 
  We determined the crystal structures of the catalytic do-
main of human TPH1 in complex with three novel TPH in-
hibitors. The structures of TPH1 in these complexes resem-
ble the structure of the chicken TPH1 (3E2T) co-crystallized 
with tryptophan and iron ion (3E2T) more than that of hu-
man TPH1 bound with BH2 and iron ion (1MLW). Superpo-
sition of all five structures shows that the enzyme adopts a 
more compact structure when bound with either the phenyla-
lanine-based inhibitors or tryptophan than by the pterin ana-
logue BH2. In all three inhibitor-TPH1 structures, the loop 
Ile336-Phe369 moved toward the loop Phe263-Pro266, clos-
ing around the amino acid binding pocket when compared to 
the TPH1-BH2-Fe(III) structure. Such a movement was also 
observed in the chicken TPH1-Trp-Fe(III) structure. Another 
large structural change observed in the chicken TPH1-Trp-
Fe(III) structure is the movement of the loop Leu124-
Asp139 toward the catalytic site [12]. Unfortunately, this 
loop was not resolved in any of the three inhibitor-TPH1 
structures due to poor electron density. Such a movement is 
suggested to have also occurred in these structures, given the 
confirmed movement of the Ile336-Phe369 loop and the 
similarity in interactions between the phenylalanine moiety 
of the inhibitors and tryptophan with the enzyme. Since 
phenylalanine is also an effective substrate of TPH1 with its 
catalytic domain showing comparable V/K and Vmax for the 
two amino acids [18], it is not surprising that the structures 
of the enzyme bound with the phenylalanine-based inhibitors 
are more similar to the one bound with Trp.  
  The pattern of the iron ion coordination is different 
among the three complexes. Two of the structures (3HF6 and 
3HFB) show a monodentate coordination by Glu317, identi-
cal to the pattern in TPH1-BH2-Fe(III) and PAH-BH4-
Fe(II). In contrast, in the structure of LP-533401-TPH1 
(3HF8), Glu317 has a bidentate interaction with the metal, 
making the coordination geometry very distorted. Such a 
bidentate interaction was also observed in the structures of 
the complexes PAH-BH4-THA-Fe(II) and TPH1-Trp-Fe(III) 
[9, 12, 14]. In the bidentate interaction mode, iron ion is only 
coordinated to five sites, allowing one open site for oxygen 
[12]. Interestingly, the mechanism of catalysis by these aro-
matic amino acid hydroxylases is hypothesized to have a 
step that involves the formation of a Fe(II)-O-O-BH4 inter-
mediate for oxygen activation followed by the formation of 
Fe(IV)O for hydroxylation [6]. Therefore, it is tempting to 
suggest that of the three inhibitors, LP-533401 binds to the 
enzyme in a conformation that is closest to its catalytic state. 
  The other major difference among the three structures is 
the conformation of Tyr235. This residue is conserved in all 
known TPH1 and TPH2 sequences. In PAH and TH, this 
position is leucine. When Tyr235 was changed to an alanine 
or leucine, the mutant enzyme showed much lower specific 
activity (~5% remaining) and increased Km for Trp but de-
creased Km for BH4 [29], implying a role in both pterin and 
Trp binding. Tyr235 was indeed found to interact not only 
with pterin in the TPH1-BH2-Fe(III) structure but also with 
Trp in the TPH1-Trp-Fe(III) structure [11, 12]. In the TPH1-
LP-521834-Fe(III) structure, Tyr235 has a conformation 
similar to the one in Trp- or BH2-bound structure. However, 
in the TPH1 structures containing either LP-533401 or LP-
534193, it is rotated inward by ~90
o and forms a new hydro-
gen bond with Pro268. These results suggest that Tyr235 has 
considerable conformation freedom that may be critical to 
the reaction mechanism of TPH1. 
  The results of kinetic analysis with the three inhibitors 
clearly showed that they are all competitive versus trypto-
phan but predominantly uncompetitive versus pterin. Being 
competitive with tryptophan is entirely consistent with the 
structural data that the phenylalanine moiety of the inhibitors 
occupies the tryptophan binding site. Being uncompetitive 
with pterin is also consistent with the structural data that the 
side chains of the three compounds are not in the space 
where pterin binds. More importantly, the uncompetitive 
behavior of the three inhibitors strongly suggests that the 
substrate tryptophan and the inhibitors bind only after pterin 
is bound [28]. For TH and PAH, similar analyses were used 
to demonstrate that pterin binds before the amino acid sub-
strate does [15, 17]. Intriguingly, these co-crystal structures 
were determined in the absence of pterin, indicating that the 
inhibitors can bind to the enzyme before pterin does, at least 
at high concentrations (inhibitors were at >500 uM during 
crystallization). Similarly, when the crystal structure of 
chicken TPH1 was solved in the absence of pterin, it was 
also found to contain tryptophan, even though the authors 
suggested that tryptophan binds after biopterin during cataly-
sis [12]. No detailed kinetic studies were reported for TPH1 
before. One study showed that the product 5-HTP inhibits 
TPH1 in a mechanism that is competitive versus phenyla-
lanine but uncompetitive versus pterin [30], analogous to the 
behavior of the three inhibitors examined here. Given its 
Table 1.  Inhibition Patterns of the Three Compounds for TPH1 
Inhibitor  Varied Substrate  Fixed Substrate  Inhibition Patterns  Ki ( mean ± S.E.M, uM)
a 
LP-533401  Trp  200 uM 6-MePH4 C
b  0.31 ± 0.01 
LP-533401 6-MePH4  50 uM Trp  UC
c  0.81± 0.03  
LP-521834  Trp  200 uM 6-MePH4  C  0.036 ± 0.001 
LP-521834 6-MePH4  50 uM Trp  UC  0.19 ± 0.01 
LP-534193  Trp  200 uM 6-MePH4  C  0.030 ± 0.001 
LP-534193 6-MePH4  50 uM Trp  UC  0.17 ± 0.01 
aValues are calculated based on two independent experiments with each experiment carried out in triplicates.
 
bC, competitive. 
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structural similarity to tryptophan, 5-HTP is expected to oc-
cupy the tryptophan site, and thus to be competitive versus 
trytophan but uncompetitive versus pterin. Taken together, 
the data showed that, similar to PAH and TH, TPH1 also 
follows an ordered binding mechanism with pterin binding 
first. Our data don’t address the binding order of tryptophan 
and oxygen. 
  In summary, we have determined co-crystal structures of 
the human TPH1 catalytic domain with three inhibitors. The 
three inhibitors all have a phenylalanine moiety which occu-
pies the tryptophan binding site of the enzyme. All three 
complexes showed an overall structure that is more similar 
to that of chicken TPH1 bound with tryptophan rather than 
that of human TPH1 bound with pterin, reflecting the struc-
tural similarity between the inhibitors and tryptophan, and 
the major conformational change induced by the binding of 
the amino acid substrate and its analogue. Kinetic analysis 
showed that all three inhibitors are competitive versus tryp-
tophan but largely uncompetitive with pterin, consistent with 
the structural data and suggestive of an ordered binding 
mechanism in which tryptophan must bind after pterin in 
order for a productive complex to form. The data shed im-
portant light on the mechanism of TPH1 catalysis and inhibi-
tion. 
ABBREVIATIONS 
6-MePH4 =  6-methyl-5,6,7,8-tetrahydropterin 
BH2 =  7,8-tetrahydrobiopterin 
BH4 =  5,6,7,8-tetrahydrobiopterin 
PAH =  phenylalanine  hydroxylase 
Phe =  L-phenylalanine 
TH =  tyrosine  hydroxylase 
THA =  3-(2-thienyl)-L-alanine 
TPH1  =  tryptophan hydroxylase type I 
Trp =  L-tryptophan 
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